The role of ApoE has been well-studied outside of the cell, but what happens after it’s let inside? Scientists led by Raimund Dutzler, University of Zurich, have identified Tweety homologue 2 as an ...

SAAs can predict cognitive decline in Parkinson’s disease. Low-level α-synuclein co-pathology was detected in CSF of progressive supranuclear palsy patients. These assays could help scientists select ...

Every participant in the Dutch 100-Plus study is, by definition, exceptional. Just to qualify for enrollment, they must have remained cognitively healthy even after logging 100 laps around the sun.

Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...

Comments ApoE and Tweety Homolog 2—Proteins that Flock Together? 11 Jul 2025 ...

To satisfy the incessant energy demands of their thousands of synapses, neurons have to have enormous supplies of ATP at the ready. Where does this seemingly bottomless well of energy come from? It’s ...

PSEN1 encodes presenilin-1, a subunit of γ-secretase, the aspartyl protease responsible for Aβ generation. More than 300 mutations in PSEN1 have been reported and mutations in PSEN1 are the most ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to conferences@alzforum.org ...

Postdoctoral Position- Neurobiology of Parkinson’s Disease JOB 2025-07-09 Employer Université Laval Contact aurelie.jacquet@crchudequebec.ulaval.ca Description The team specializes in the study of ...

Over the last 40 years, age-adjusted dementia prevalence in the U.S. has dropped by two-thirds. This predicts a 25 percent rise in total dementia cases by 2050, due to population aging. The findings ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...